AJOVista LLC Acquires Shares of 7,609 Cogent Biosciences, Inc. (NASDAQ:COGT)

AJOVista LLC acquired a new position in Cogent Biosciences, Inc. (NASDAQ:COGT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,609 shares of the technology company’s stock, valued at approximately $45,000.

Several other large investors also recently made changes to their positions in COGT. Fisher Asset Management LLC lifted its position in Cogent Biosciences by 48.1% during the 4th quarter. Fisher Asset Management LLC now owns 101,531 shares of the technology company’s stock worth $597,000 after buying an additional 32,962 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Cogent Biosciences by 67.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,934 shares of the technology company’s stock worth $111,000 after purchasing an additional 7,606 shares during the last quarter. Cornercap Investment Counsel Inc. acquired a new position in Cogent Biosciences during the 4th quarter worth $202,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Cogent Biosciences by 34.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,467 shares of the technology company’s stock valued at $285,000 after buying an additional 12,293 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Cogent Biosciences by 355.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,961 shares of the technology company’s stock valued at $59,000 after buying an additional 7,772 shares during the period.

Analyst Ratings Changes

Several brokerages have weighed in on COGT. Needham & Company LLC reissued a “buy” rating and set a $18.00 price objective on shares of Cogent Biosciences in a report on Monday, February 26th. Robert W. Baird reaffirmed a “neutral” rating and issued a $8.00 price objective (down from $14.00) on shares of Cogent Biosciences in a research note on Monday, February 26th. Leerink Partnrs reissued an “outperform” rating on shares of Cogent Biosciences in a research note on Thursday, February 22nd. Wedbush upped their price objective on Cogent Biosciences from $5.00 to $10.00 and gave the company a “neutral” rating in a report on Friday, February 23rd. Finally, JPMorgan Chase & Co. boosted their target price on Cogent Biosciences from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Cogent Biosciences currently has an average rating of “Moderate Buy” and an average target price of $13.67.

Cogent Biosciences Trading Up 0.3 %

Shares of COGT opened at $7.55 on Monday. The stock has a 50 day simple moving average of $6.73 and a 200 day simple moving average of $6.63. Cogent Biosciences, Inc. has a 52-week low of $3.67 and a 52-week high of $13.50.

Cogent Biosciences (NASDAQ:COGT) last released its earnings results on Monday, February 26th. The technology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.08). As a group, equities research analysts anticipate that Cogent Biosciences, Inc. will post -1.89 earnings per share for the current fiscal year.

Cogent Biosciences Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.